{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:19:02Z","timestamp":1791350342519,"version":"4.3.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,1,11]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">High\u2010potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high\u2010potency statins after acute coronary syndromes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              The Stabilization of pLaques usIng Darapladib\u2010Thrombolysis in Myocardial Infarction (SOLID\u2010TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high\u2010potency statin was defined as \u226540\u00a0mg atorvastatin, \u226520\u00a0mg rosuvastatin, or 80\u00a0mg simvastatin daily. Predictors of nonuse of high\u2010potency statins were examined using logistic regression. Of the patients included (n=12\u00a0446), 11\u00a0850 (95.2%) were treated with a statin at baseline after acute coronary syndrome (median 14\u00a0days), but only 5212 (41.9%) were on a high\u2010potency statin. Selected patient factors associated with nonuse of high\u2010potency statins included age \u226575\u00a0years (odds ratio 1.39, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              1.24\u20131.56), female sex (odds ratio 1.11, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              1.02\u20131.22), renal dysfunction (odds ratio 1.17, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              1.03\u20131.32), and heart failure during hospital admission (odds ratio 1.43, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              1.27\u20131.62). At 3\u00a0months after baseline, only 49% of patients had low\u2010density lipoprotein cholesterol &lt;70\u00a0mg\/dL. Among the 5490 patients (59%) who were not on a high\u2010potency statin at 3\u00a0months, lower low\u2010density lipoprotein cholesterol was a predictor of nonuse of a high\u2010potency statin after a median of 2.3\u00a0years (odds ratio 1.15 for 10\u00a0mg\/dL decrease, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              1.11\u20131.19).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p xml:lang=\"en\">Despite the widespread use of statins after acute coronary syndromes, most patients are not treated with high\u2010potency statins early and late after the event, including patients at the highest risk of recurrent cardiovascular events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Clinical Trial Registration<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              <jats:styled-content style=\"fixed-case\">URL<\/jats:styled-content>\n              :\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier:\n              <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>\n              01000727.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.116.004332","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T02:42:16Z","timestamp":1484188936000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Predictors of Nonuse of a High\u2010Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib\u2010Thrombolysis in Myocardial Infarction 52 (SOLID\u2010TIMI 52) Trial"],"prefix":"10.1161","volume":"6","author":[{"given":"Alon","family":"Eisen","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan L.","family":"Steen","sequence":"additional","affiliation":[{"name":"University of Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Goodrich","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungAh","family":"Im","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Dalby","sequence":"additional","affiliation":[{"name":"Milpark Hospital, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Spinar","sequence":"additional","affiliation":[{"name":"University Hospital Brno, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Daga","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Lukas","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O'Donoghue","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1307"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr236"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.601"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.044"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.088"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.12.020"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003589"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.12.014"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.11061"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.07.018"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61190-8"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm161"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.013"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.188209"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.116.004332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:44:18Z","timestamp":1715597058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.116.004332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,11]]}},"alternative-id":["10.1161\/JAHA.116.004332"],"URL":"https:\/\/doi.org\/10.1161\/jaha.116.004332","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]},"assertion":[{"value":"2016-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e004332"}}